Biostage, Inc. (OTCQB: BSTG) is a pioneering biotechnology company developing bioengineered organ implants to address unmet needs in the treatment of life-threatening cancer, traumas and congenital abnormalities of the esophagus, bronchus and trachea.
The company’s Cellframe™ technology platform is engineered to stimulate the body’s signaling pathways and natural healing process to regenerate and restore organ function. Combining a synthetic scaffold with tissue engineering and cell biology, Biostage’s Cellframe™ platform is used to create organ specific Cellspan™ implants.
The Cellspan™ implant is delivered directly to the site where tissue regeneration is needed, and has been designed to promote in situ tissue regeneration by providing both stem cell-derived biological signals, and three-dimensional guidance and support for cell growth differentiation. Recent large animal data delivered promising results as Cellframe™-based Cellspan™ implants applied to the esophagus achieved regeneration of esophageal tissue.
The company is currently expanding its preclinical data in collaboration with Mayo Clinic, and intends to submit an IND with the FDA for its first indication by end of second quarter 2017.
Regenerative Medicine; Hollow Organ Implants
Holliston, MA, United States